Small molecule antagonists of the gonadotropin-releasing hormone (GnRH) receptor: Structure-activity relationships of small heterocyclic groups appended to the 2-phenyl-4-piperazinyl-benzimidazole template

被引:10
|
作者
Hauze, Diane B. [1 ]
Chengalvala, Murty V. [2 ]
Cottom, Joshua E. [2 ]
Feingold, Irene B. [3 ]
Garrick, Lloyd [1 ]
Green, Daniel M. [1 ]
Huselton, Christine [3 ]
Kao, Wenling [1 ]
Kees, Kenneth [1 ]
Lundquist, Joseph T. [1 ]
Mann, Charles W. [1 ]
Mehlmann, John F. [1 ]
Rogers, John F. [1 ]
Shanno, Linda [2 ]
Wrobel, Jay [1 ]
Pelletier, Jeffrey C. [1 ]
机构
[1] Wyeth Ayerst Res, Dept Chem & Screening Sci, Collegeville, PA 19426 USA
[2] Wyeth Ayerst Res, Dept Musculoskeletal Biol, Collegeville, PA 19426 USA
[3] Wyeth Ayerst Res, Dept Drug Safety & Metab, Collegeville, PA 19426 USA
关键词
Gonadotropin releasing hormone (GnRH) receptor; 2-Phenyl-4-piperazinyl-benzimidazole; INHIBITORS; ASSAYS;
D O I
10.1016/j.bmcl.2009.02.043
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A previous report described the serum LH suppression pharmacology of the 2-phenyl-4-piperazinyl-benzimidazole N-ethyluracil GnRH receptor antagonist 1 following oral administration in rats. A series of small heterocycles were appended to the 2-(4-tert-butylphenyl)-4-piperazinyl-benzimidazole template in place of the N-ethyluracil. Two imidazole analogues, 32 and 41, were shown to possess substantial in vitro potency at the target receptor (hGnRH IC(50) = 7 and 18 nM, respectively) and aqueous solubility (55 and 100 mu g/mL at pH 7.4, respectively). Both compounds had high oral bioavailability in rats and 32 was further examined in an orchidectomized rat model for serum LH suppression based on increased volume of distribution over 41. Serum LH levels trended lower in orchidectomized rats following oral administration of 32. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1986 / 1990
页数:5
相关论文
共 34 条
  • [31] Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 1: Discovery and initial structure-activity relationships for 1-amino-2-phenyl-4-(piperidin-1-yl)butanes
    Dorn, CP
    Finke, PE
    Oates, B
    Budhu, RJ
    Mills, SG
    MacCoss, M
    Malkowitz, L
    Springer, MS
    Daugherty, BL
    Gould, SL
    DeMartino, JA
    Siciliano, SJ
    Carella, A
    Carver, G
    Holmes, K
    Danzeisen, R
    Hazuda, D
    Kessler, J
    Lineberger, J
    Miller, M
    Schleif, WA
    Emini, EA
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (02) : 259 - 264
  • [32] Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)
    De Lucca, George V.
    Shi, Qing
    Liu, Qingjie
    Batt, Douglas G.
    Bertrand, Myra Beaudoin
    Rampulla, Rick
    Mathur, Arvind
    Discenza, Lorell
    D'Arienzo, Celia
    Dai, Jun
    Obermeier, Mary
    Vickery, Rodney
    Zhang, Yingru
    Yang, Zheng
    Marathe, Punit
    Tebben, Andrew J.
    Muckelbauer, Jodi K.
    Chang, ChiehYing J.
    Zhang, Huiping
    Gillooly, Kathleen
    Taylor, Tracy
    Pattoli, Mark A.
    Skala, Stacey
    Kukral, Daniel W.
    McIntyre, Kim W.
    Salter-Cid, Luisa
    Fura, Aberra
    Burke, James R.
    Banish, Joel C.
    Carter, Percy H.
    Tino, Joseph A.
    JOURNAL OF MEDICINAL CHEMISTRY, 2016, 59 (17) : 7915 - 7935
  • [33] Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylamino-pyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure-activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists
    Chen, C
    Wilcoxen, KM
    Huang, CQ
    Xie, YF
    McCarthy, JR
    Webb, TR
    Zhu, YF
    Saunders, J
    Liu, XJ
    Chen, TK
    Bozigian, H
    Grigoriadis, DE
    JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (19) : 4787 - 4798
  • [34] Antagonists of the human CCR5 receptor as anti-HIV-1 agents.: Part 4:: Synthesis and structure-activity relationships for 1-[N(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N- (benzyloxycarbonyl)amino)piperidin-1-yl)butanes
    Finke, PE
    Oates, B
    Mills, SG
    MacCoss, M
    Malkowitz, L
    Springer, MS
    Gould, SL
    DeMartino, JA
    Carella, A
    Carver, G
    Holmes, K
    Danzeisen, R
    Hazuda, D
    Kessler, J
    Lineberger, J
    Miller, M
    Schleif, WA
    Emini, EA
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (18) : 2475 - 2479